I-Mab Logo
Contact Us For inquiries, get in touch with our team
  • Who We Are

    A global innovative biotech company

  • Value Creation

    Laser-focused on delivering innovative therapies to patients in need

  • Leadership Team

    A world-class global leadership team

  • People and Culture

    People are the cornerstone of our success

  • Commitment to ESG

    Committed to the highest environmental, social and governance standard

  • Science

    Our cutting-edge science focuses on fine-tuning the immune network in cancer

  • Operations

    An integrated research, development, manufacturing and commercialisation strategy

  • Publications & Presentations

    A compilation of our latest publications and presentations

  • Pipeline

    We have an innovative and advanced immuno-oncology clinical pipeline

  • Clinical Trials

    We work closely with global investigators to carefully conduct and monitor clinical studies

  • Partnerships

    We partner to deliver innovative medicines that transform patients' lives

  • News
  • Events
  • Mission and Values
  • Highlights
  • Global Footprint
  • Awards
  • Value Creation Model
  • Value Creation Enabler
  • Management Team
  • Board of Directors
  • Scientific Advisory Board
  • Employee Development
  • Employee Wellness
  • Diversity, Inclusion and Equity
  • T+ Excellent Employer Award
  • Patients
  • Philanthropy
  • People
  • ESG Policies
  • Unmet Needs
  • Cutting-Edge Science
  • Key Products
  • Lemzoparlimab (TJC4)
  • Uliledlimab (TJD5)
  • Givastomig (TJ-CD4B)
  • Efineptakin alfa (TJ107)
  • TJ-C64B
  • Enoblituzumab (TJ271)
  • TJ-C4GM
  • TJ-L1I7
  • Hematologic Malignancies
  • Solid Tumors
  • Other Assets
  • Putting Patients First
  • Advancing Clinical Research
  • Selected Ongoing Clinical Trials
  • Strategic Partnering Model
  • Landmark Deals
  • Our Partners
  • Press Releases
  • Media Reports
  • Partner News
About Innovation Products Partnerships Newsroom
Investors Careers Contact Us
  • 中
I-Mab Logo
  • About
    • Who We Are
    • Value Creation
    • Leadership Team
    • People and Culture
    • Commitment to ESG
  • Innovation
    • Science
    • Operations
    • Publications & Presentations
  • Products
    • Pipeline
    • Clinical Trials
  • Partnerships
  • News & Events
    • News
    • Events
  • Investors
  • Careers
  • Contact
  • 中

Press Releases

  • Press Releases
  • Media Reports
  • Partner News

2023.03.20

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

The Company announced date of reporting financial results for year 2022.

2023.03.13

I-Mab Confirms No Banking Relationship with Silicon Valley Bank

I-Mab today issued a statement on the recent developments of the SVB.

2023.03.07

I-Mab Receives “A” Rating in Updated MSCI ESG Assessment

I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.

2022.11.03

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.

2022.10.05

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

I-Mab will present new preclinical data of its core assets lemzoparlimab and uliledlimab at the 37th SITC Annual Meeting.

2022.09.13

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.

2022.09.10

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

I-Mab today announces encouraging data from its Phase 2 clinical trial of lemzoparlimab in combination with azacitidine in patients with newly diagnosed HR-MDS.

2022.09.06

I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

I-Mab today announced that the results from its Phase 2 clinical study of lemzoparlimab in combination with azacitidine in patients with HR-MDS will be featured in a proffered paper presentation at the upcoming ESMO Congress 2022.

2022.08.30

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

I-Mab today announced financial results for the six months ended June 30, 2022, and provided key business updates.

2022.08.23

I-Mab Announces Share Purchase Plans by the Company and the Senior Management

I-Mab today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors.

Posts navigation

1 2 … 18 Next

Sitemap

  • Home
  • About
  • Innovation
  • Products
  • Partnerships
  • News & Events
  • Investors
  • Careers
  • Contact
  • 中

Follow Us

  • LinkedIn
  • Twitter

Copyright © 2023 I-MAB Biopharma Co., Ltd. All Rights Reserved.

沪ICP备17007960号-2 | 沪公网安备31011502018701号